Galderma Group AG (SWX:GALD)

Market Cap	27.33B
Revenue (ttm)	4.02B
Net Income (ttm)	209.33M
Shares Out	237.41M
EPS (ttm)	0.88
PE Ratio	130.95
Forward PE	48.48
Dividend	0.15 (0.13%)
Ex-Dividend Date	Apr 25, 2025

Volume	334,108
Average Volume	627,464
Open	115.60
Previous Close	115.10
Day's Range	115.60 - 118.70
52-Week Range	64.75 - 119.60
Beta	n/a
RSI	72.26
Earnings Date	Jul 24, 2025

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 6,545
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: GALD

Financial Performance

Financial numbers in USD